Is dasatinib (Tasatinib) a targeted drug or a chemotherapy drug?

Dasatinib (Dasatinib) is a targeted drug, not a traditional chemotherapy drug. Targeted drugs are drugs designed to target specific molecular targets, and their mechanisms of action are different from traditional chemotherapy drugs.

As a tyrosine kinase inhibitor, dasatinib (Startase) works mainly by inhibiting abnormally active tyrosine kinases in leukemia cells. In patients with chronic myelogenous leukemia (CML), the common abnormal gene is Philadelphiachromosome-positive (Ph+ ), leading to the production of BCR-ABL fusion gene, which is one of the main factors causing CML. Dasatinib (Startase) can target the BCR-ABLkinase product of this fusion gene and inhibit its activity, thereby reducing the proliferation and survival of abnormal leukemia cells and delaying the progression of the disease.

Compared with traditional chemotherapy drugs, targeted drugs have a more precise mechanism of action and can selectively act on specific targets of cancer cells, reducing damage to normal cells, thus reducing the toxic and side effects during treatment. In addition, targeted drugs are often more effective at inhibiting the growth and spread of cancer cells, improving treatment effects, and to a certain extent, prolonging patients' survival and improving their quality of life.

However, althoughDasatinib (Stardas) is a targeted drug, patients may still experience some adverse reactions during use, such as nausea, vomiting, diarrhea, fatigue, etc., as well as some more serious side effects, such as thrombocytopenia, abnormal liver function, etc. Therefore, when using dasatinib or other targeted drugs, patients need to be closely monitored and follow their doctor's recommendations for treatment.

In general,dasatinib (Stacer) as a targeted drug, has a precise mechanism of action and low toxic and side effects, and is of great significance for the treatment of chronic myelogenous leukemia and other related diseases, but patients still need to pay attention to monitoring and controlling potential adverse reactions when using it.